Advertisement

U.S. Markets closed

S&P Futures
5,887.00
-9.25(-0.16%)
Dow Futures
43,129.00
-48.00(-0.11%)
Nasdaq Futures
20,469.25
-50.25(-0.24%)
Russell 2000 Futures
2,250.50
-5.00(-0.22%)
Crude Oil
70.30
-0.26(-0.37%)
Gold
2,743.60
+4.70(+0.17%)

ADVM Nov 2024 8.000 call

OPR - OPR Delayed Price. Currency in USD

0.9700

0.0000

(0.00%)

As of 12:36PM EDT. Market open.

GlobeNewswire
Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program
REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced the appointment of Jason L. Mitchell as chief commercial officer. Mr Mitchell brings to Adverum over 20 years of commercial experience, including in retinal disease, and most recently oversaw the successful launch of SYFOVRE® in geographic atrophy (GA). In his new role, Mr
Zacks
Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.